Segment Information - Schedule of Financial Data for Business Segments (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended		3 Months Ended									9 Months Ended
	Dec. 31, 2014 segment	Dec. 31, 2013 segment	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 28, 2012
Segment Reporting Information [Line Items]
Number of business segments	2	2
Successor [Member]
Segment Reporting Information [Line Items]
Total revenues	1,308,621	1,097,467	$ 388,015	$ 336,117	$ 295,405	$ 289,084	$ 306,281	$ 267,321	$ 233,669	$ 290,196	$ 246,139
Gross margin	479,115	318,043	150,467	140,825	93,509	94,314	106,308	81,391	58,900	71,444	45,445
Operating (loss) income	(66,612)	(65,443)	17,945	(32,875)	(17,527)	(34,155)	(41,828)	(24,725)	(7,499)	8,609	(29,763)
Gain on marketable securities and other investments, net	0	1,122									0
Gain on bargain purchase	0	0									5,500
Interest income	18	87									50
Interest expense	(108,427)	(95,484)									(25,985)
Loss on debt extinguishment	(3,989)	(7,335)									0
Other income	500	0									0
(Benefit) provision for income taxes	(72,993)	(61,182)									(17,653)
Net (loss) income	(105,517)	(105,871)									(32,545)
Successor [Member] | Par Pharmaceutical [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	1,241,131	1,028,418									227,312
Gross margin	436,078	271,396									33,776
Operating (loss) income	(30,938)	(48,082)									(25,938)
Successor [Member] | Par Specialty [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	67,490	69,049									18,827
Gross margin	43,037	46,647									11,669
Operating (loss) income	(35,674)	(17,361)									(3,825)
Predecessor [Member]
Segment Reporting Information [Line Items]
Total revenues												803,868
Gross margin												342,350
Operating (loss) income												59,440
Gain on marketable securities and other investments, net												0
Gain on bargain purchase												0
Interest income												424
Interest expense												(9,159)
Loss on debt extinguishment												0
Other income												0
(Benefit) provision for income taxes												29,530
Net (loss) income												21,175
Predecessor [Member] | Par Pharmaceutical [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues												743,360
Gross margin												296,338
Operating (loss) income												116,591
Predecessor [Member] | Par Specialty [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues												60,508
Gross margin												46,012
Operating (loss) income												$ (57,151)